Fairir Biotech

Fairir Biotech is a China-based biotechnology company specializing in the discovery and development of next-generation targeted protein degradation (TPD) therapies, with a primary focus on molecular glues. The company leverages a proprietary platform that integrates high-throughput screening, structural biology, and computational chemistry to identify small molecules capable of inducing the degradation of previously undruggable disease-causing proteins. Fairir Biotech's pipeline is currently in the pre-clinical stage, targeting high-value indications in oncology and immunology. By focusing on molecular glue degraders, the company aims to overcome the limitations of traditional occupancy-based inhibitors and PROTACs.